NYSE$TAK

Takeda Pharmaceutical Co Ltd-ADR · Q1 2027 earnings

Q1 2027 earnings · · Investor relations

Briefing

Takeda reported solid Q1 FY2026 results with revenue growth on an actual exchange rate basis driven by core brands offsetting VYVANSE loss of exclusivity.

Takeda Pharmaceutical announced its first quarter fiscal 2026 results on July 30, 2026, showing revenue of JPY 1.22 trillion, up 10.2% year-over-year on an AER basis. Core operating profit rose 11.5% AER to JPY 358.9 billion, while reported net profit declined 8.9% to JPY 113.2 billion. The company maintained its full-year guidance unchanged and highlighted progress on its late-stage pipeline.

  • Revenue reached JPY 1,219.9 billion (+10.2% AER, -0.5% CER) as core in-line brands offset VYVANSE LOE impact.
  • Core operating profit was JPY 358.9 billion (+11.5% AER); reported operating profit JPY 201.4 billion (+9.1% AER).
  • Reported EPS JPY 71.65 and core EPS JPY 154; full-year forecast and management guidance unchanged.
  • Pipeline milestones advanced with first approval for ORZEYFUL in China and launch preparations on track for multiple assets.

Headline financials

Total Revenue

¥7.49B

No prior period
EPS (adj)

¥154.00

No prior period
Net Income

¥695M

No prior period
Operating Income

¥1.24B

No prior period

Revenue & EPS history

Takeda · Revenue · Quarterly

¥7.49B

Q1 2027
Beat estimate in 1 of 2 quarters(50%)
ActualEstimate

Forward guidance

No changes to FY2026 full-year forecast; management guidance at CER expects low-single digit % decline in core revenue, 5-8% decline in core operating profit, and mid-teens % decline in core EPS.

Tailwinds

  • Resilient core in-line portfolio performance
  • Transformation program delivering OPEX savings for reinvestment
  • Pipeline progress on track with key approvals and submissions expected

Headwinds

  • Mature portfolio declines including VYVANSE LOE
  • Continued investment in launches and R&D pressuring near-term margins at CER

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports

Historical avg

-0.7%

Avg return

Earnings day

-0.8%

Avg return

5 days after

+0.3%

Avg return

30 days after

39%

24 / 62 earnings

Positive

+6.3%

Q1 2019

Best reaction

-7.5%

Q4 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2027
Q4 2027-1.4%-2.1%-5.8%
Q3 2026+1.5%-4.6%+0.1%
Q2 2025-3.9%-1.5%+4.7%
Q1 2025-4.2%-0.4%+4.7%
Q4 2024-5.1%-8.9%-0.7%
Q1 2024+1.5%+1.2%+9.1%
Q4 2023+1.5%+3.0%+3.1%
Q3 2023-2.2%-3.0%-0.3%
Q2 2023-7.1%-6.2%-3.2%
Q1 2023-0.9%-2.1%-1.4%
Q4 2022-3.5%-3.1%-4.5%
Q3 2022+0.8%+0.4%-1.5%
Q2 2022+1.8%+2.4%+12.4%
Q1 2022-0.5%-4.8%-6.7%
Q4 2021-1.8%-1.7%-7.8%
Q3 2021+0.5%+3.2%+2.9%
Q2 2021+1.4%+2.8%-2.1%
Q1 2021-1.1%-2.5%-1.8%
Q4 2020-0.7%+0.9%+2.4%
Q3 2020-1.4%+1.6%+0.2%
Q2 2020-4.4%-1.6%+11.6%
Q1 2020+2.0%+1.5%+3.4%
Q4 2019+5.5%-0.9%+3.8%
Q3 2019+3.2%+4.4%-7.6%
Q2 2019+3.3%+6.6%+12.3%
Q1 2019+6.3%+3.6%+0.5%
Q4 2018-7.5%-10.4%-11.0%
Q2 2018-3.0%-6.9%-5.5%
Q1 2018-1.7%-0.3%-1.2%
Q4 2017-2.7%+1.1%-13.1%
Q3 2017+0.4%+2.5%+5.3%
Q2 2017-0.9%-0.3%+2.3%
Q1 2017-0.8%-2.2%+3.1%
Q4 2016-1.5%-0.8%+3.0%
Q3 2016+0.1%+2.3%+1.3%
Q2 2016-0.2%-0.9%-3.4%
Q1 2016-1.6%-0.6%+4.0%
Q4 2015-4.6%
Q3 2015-2.0%
Q2 2015+1.4%
Q1 2015+1.1%
Q4 2014-3.7%
Q3 2014-0.7%
Q2 2014-1.6%
Q1 2014+1.1%
Q4 2013-2.7%
Q3 2013-0.7%
Q2 2013-0.3%
Q1 2013+1.2%
Q4 2012-6.4%
Q3 2012+1.6%
Q2 2012-1.2%
Q1 2012+0.0%
Q4 2011-0.9%
Q3 2011+1.0%
Q2 2011-0.7%
Q1 2011+1.5%
Q4 2010-2.5%
Q3 2010+1.4%
Q2 2010-0.2%
Q1 2010+1.7%
Q4 2009-0.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro